INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 25 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $14,452,000 | +27.1% | 20,000,000 | +53.8% | 0.24% | +4.3% |
Q1 2020 | $11,372,000 | +150.8% | 13,000,000 | +160.0% | 0.23% | +184.0% |
Q3 2019 | $4,535,000 | -54.5% | 5,000,000 | -50.0% | 0.08% | -56.2% |
Q2 2019 | $9,957,000 | – | 10,000,000 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |